Expert Interviews

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Elizabeth Dennis, MSN, APRN, FNP-C, shares how she manages amivantamab plus lazertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer, starting with prevention on day 1.

Elizabeth Dennis, MSN, APRN, FNP-C, reviews longer follow-up safety data from the COPERNICUS study and links the adverse events of amivantamab plus lazertinib to their mechanisms in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Elizabeth Dennis, MSN, APRN, FNP-C, describes what distinguishes the COPERNICUS study from the MARIPOSA trial in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: a focus on treatment implementation, not only efficacy.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Elizabeth Dennis, MSN, APRN, FNP-C, explains how overall survival data from the MARIPOSA trial changed the first-line conversation for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and multidisciplinary strategies needed to successfully implement advances in the frontline management of metastatic triple-negative breast cancer (mTNBC).

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

NP Theresa Stukus and NP Nelli Zafman discuss the practical challenges patients with metastatic triple-negative breast cancer (mTNBC) may encounter during prolonged antibody-drug conjugate (ADC) therapy and the critical role of the multidisciplinary care team in supporting long-term treatment success.

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing, monitoring, and managing oral and ocular toxicities in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate therapy.

This closing segment follows the patient into surveillance as he and his wife worry about recurrence.

This segment addresses recognizing and managing adverse events, with nurses described as the care team's eyes on the ground.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic triple-negative breast cancer (mTNBC) who is experiencing ongoing treatment-related toxicities while maintaining disease control on frontline therapy.

NP Theresa Stukus and NP Nelli Zafman discuss how the distinct toxicity profiles of available antibody-drug conjugates (ADCs) influence supportive care strategies for patients with metastatic triple-negative breast cancer (mTNBC).

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.

This segment compares the practical logistics of delivering intravesical therapies and encourages clinics to identify treatment champions among pharmacy, clinic, and provider staff.

This segment returns to the patient case to explore alternatives to repeat surgery.

At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.

ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.